

## **ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®**

GHENT, Belgium, 13 September 2024 – **ProDigest has been awarded a contract to provide a SHIME® (Simulator of Human Intestinal Microbial Ecosystem) technology platform for full gut simulation to the US Food and Drug Administration (FDA), National Center for Toxicological Research.**

The SHIME® model is currently the most representative validated *in vitro* technology for the combined simulation of the physiological, chemical and microbiological properties of the full gastrointestinal tract. The model enables study of the impact of long-term repeated dosing and of the modulation of the microbiota in function of the gut location. The SHIME® can be seen as a clinical trial *in vitro*, which can provide the spatio-temporal insight into the mechanism of action of a specific treatment, therefore providing complementary data to *in vivo* studies.

*“This is another important milestone in the history of ProDigest showing the value that our technology platforms can have for the private and public sectors”,* stated Massimo Marzorati, CEO of ProDigest.

SHIME® is characterized by a high flexibility to adapt to multiple experimental designs, to best fit specific research questions (i.e. TwinSHIME®; TripleSHIME®; QuadSHIME®; ScreeningSHIME®).

*“Together with the Colon-on-a-plate® (a high-throughput colonic simulation), MetaKey® (a unique metabolomic platform) and multiple cell models, we are able to provide the broadest offering on the market in terms of in vitro/ex vivo gut simulation to support our clients with the best scientific answers to their research questions”* concluded Massimo Marzorati.

To learn more about ProDigest please visit [www.prodigest.eu](http://www.prodigest.eu) and follow [www.linkedin.com/company/prodigest](https://www.linkedin.com/company/prodigest)

- Ends -

### **About ProDigest**

ProDigest is a product leader in the development of unique laboratory models of the human and animal gastrointestinal tract (SHIME®; Colon-on-a-plate®). These models allow to obtain unique insight in gut processes associated to the intestinal fate of actives and its link with host's health. ProDigest is globally active as a service provider for food and pharmaceutical companies and since 2014 also installs its technology in selected R&D facilities around the world. In 2021, ProDigest launched a new business unit, MetaKey®, for integrated metabolomics services.